CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 173 enrolled
Drug / intervention
ESBA1008 solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01796964
NCT01796964Phase 2Completed
CompareCT.gov

A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA® in Subjects With Exudative Age-Related Macular Degeneration

Alcon Research·interventional·Posted Feb 22, 2013·Updated Feb 9, 2016

In Brief

A Phase 2 clinical trial evaluating ESBA1008 solution and Aflibercept for Exudative Age-Related Macular Degeneration. Completed, enrolled 173 participants.

Detailed Summary

The purpose of this study is to compare the efficacy and safety of ESBA1008 versus EYLEA® in the treatment of exudative age-related macular degeneration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExudative Age-Related Macular Degeneration
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 22, 2013
Enrollment StartMar 1, 2013
Primary CompletionOct 1, 2013
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.4 years ago

Interventions

ESBA1008 solutiondrug

For intravitreal (IVT) injection

Afliberceptdrug

For intravitreal (IVT) injection